Monday 22 April 2019

Largest Trial of CD22 CAR T-Cell Therapy Shows Efficacy, New Toxicity Concerns - Clinical Oncology News

Largest Trial of CD22 CAR T-Cell Therapy Shows Efficacy, New Toxicity Concerns  Clinical Oncology News

CD22 chimeric antigen receptor (CAR) T-cell therapy led to complete remission in 84% of patients with refractory or recurrent acute lymphoblastic leukemia ...

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)